Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors.

ABSTRACT: Tisotumab vedotin is an investigational antibody-drug conjugate (ADC) for treatment of solid tumors expressing tissue factor with accelerated approval from the US Food and Drug Administration for treatment of recurrent or metastatic cervical cancer with disease progression during or after chemotherapy. This study describes development of a population pharmacokinetic (PK) model to assess the PK profile of tisotumab vedotin and microtubule-disrupting agent monomethyl auristatin E (MMAE) using data from 399 patients with solid tumors across four phase I/II trials. The ADC-MMAE model describes ADC and MMAE concentrations following intravenous administration of tisotumab vedotin. This four-compartment model comprises a two-compartment ADC model with parallel linear and Michaelis-Menten eliminat

SUBMITTER: Gibiansky L 

PROVIDER: S-EPMC9574719 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature